367 related articles for article (PubMed ID: 16361539)
1. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
4. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
[TBL] [Abstract][Full Text] [Related]
5. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
6. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
8. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
9. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
12. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
13. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
[TBL] [Abstract][Full Text] [Related]
15. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y
Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841
[TBL] [Abstract][Full Text] [Related]
19. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
20. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
Friedman JM; Liang G; Liu CC; Wolff EM; Tsai YC; Ye W; Zhou X; Jones PA
Cancer Res; 2009 Mar; 69(6):2623-9. PubMed ID: 19258506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]